



## Supplementary Figure Legends



**Supplementary Figure 1 Effects of BMI on the prevalence of BP, RAS, and Males.** a: The incidence rate of hypertension, b: The prevalence of RAS, c: The rate of Male sex, d: Systolic blood pressure, e: Diastolic blood pressure. BMI: body mass index, CI: confidence interval, RAS: Renin-angiotensin system blockers.



copyright©the author (s) 2023

Supplementary Figure 2 Effects of BMI on the palence of blood lipid level. a: Cholesterol, b: Triglycerid, c: Low-density lipoprotein, d: High-density lipoprotein. BMI: body mass index, CI: confidence interval.

**Supplementary Table 1 Demonstrates the quality of studies according to NOS for cohort studies**

Study	selection		Selection of controls	Definiti on of controls	comparabi lity	Exposure	Non-Res ponse rate	total
	Is the case definit ion adequ ate	Representat iveness of the cases			comparabi lity of cases and controls on the basis of the design or analysis	Ascertainm ent of exposure		
Huang W H	★	★		★	★★	★	★	8
Bentata Y	★	★		★	★★	★	★	8
Chen H M		★		★	★★		★	5
Ali Mohsen	★	★	★	★	★★		★	7
Kim BY	★	★		★	★★		★	6
Narime` ne Belhate m	★	★	★	★	★★	★	★	8

Supplementary Table 2 Demonstrates the quality of studies according to AHRQ for the eligible studies

	Define the source of information (survey, record review) previous publications	Whether the inclusion and exclusion criteria of exposed group (case and control) are listed or refer to previous publications	Indicate time period used for identifying patients participants	Indicate whether or not subjects were consecutive if not population-based	Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants	Describe any assessments undertaken for quality assurance purposes (eg.test/retest of primary outcome measurements)	Explain in any patient exclusions from analysis	Describe how confounding was assessed and/or followed up was obtained	If applicable, explain how missing data were handled in the analysis	Summarize patient response rates and completeness of data collection	Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained	Total
<u>Iefke</u>	1	1	1	1	1	1	1	1	0	1	0	9
<u>Drion</u>	1	1	1	1	1	1	0	1	0	0	0	7

Yongze Zhang	1	1	1	1	1	1	1	1	0	0	0	8
Nakanis hi S	1	1	1	1	1	1	1	1	0	0	0	8
Kanauchi M	1	1	1	1	1	1	1	1	0	0	0	8

---